RA
ADMA icon

Royce & Associates’s ADMA Biologics ADMA Stock Holding History

Royce & Associates’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,124
Closed -$244K – 748
2026
Q1 		$244K Sell
27,124
-1,207,343
-98% -$19.1M ﹤0.01% 748
2025
Q4 		$22.5M Buy
1,234,467
+302,399
+32% +$5.1M 0.23% 130
2025
Q3 		$13.7M Buy
932,068
+292,819
+46% +$5.02M 0.14% 232
2025
Q2 		$11.6M Sell
639,249
-57,752
-8% -$1.18M 0.12% 251
2025
Q1 		$13.8M Buy
697,001
+276,432
+66% +$4.78M 0.15% 200
2024
Q4 		$7.21M Buy
+420,569
New +$7.91M 0.07% 408

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Royce & Associates's ADMA Position: Q2 2026 in Review

Royce & Associates sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 27,124 shares — an estimated $244K sold.

Royce & Associates first reported a position in ADMA in Q4 2024 and held it in 6 quarters. The position peaked at $22.5M in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Royce & Associates reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Royce & Associates sold 27,124 ADMA Biologics shares in Q2 2026, an estimated $244K.
  • Royce & Associates first reported a position in ADMA Biologics in Q4 2024 and held it in 6 quarters.
  • Royce & Associates's ADMA Biologics position peaked at $22.5M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.